Sustained-release chemotherapy has potential for bladder cancer
A study has shown an intravesical sustained-release chemotherapy device demonstrated effectiveness in advanced bladder cancer.
List view / Grid view
News
NICE guidance recommends olaparib for breast and prostate cancers
PARP inhibitor olaparib has been recommended in NICE’s final draft guidance for early breast cancer and advanced prostate cancer.
Eculizumab biosimilar gets positive CHMP opinion
Samsung Bioepis’ first haematology biosimilar, which references Soliris (eculizumab), has been recommended for approval by the CHMP.
CGT supply chain and logistics market worth $3.12b by 2031
Improvements in real-time supply chain operations is expected to drive the cell and gene therapy supply chain/logistics market, a report says.
Could reducing agar concentration enhance microbial growth?
Improvements to the pour plate method during rapid microbial assessment could facilitate automation of the technique, according to research.
Monoclonal antibodies can lower COVID-19 hospitalisation risk
Over a third of COVID-19 patients reduced their risk of serious outcomes when treated early with monoclonal antibodies, a study shows.
Treatment shows strong potential for ALK-driven neuroblastoma
A Phase I study has shown significant promise in treating newly diagnosed ALK-driven high-risk neuroblastoma in paediatric patients.
CHMP meeting highlights – March 2023
In the European Medicines Agency's March human medicines committee meeting, nine new medicines were recommended, including one for multiple sclerosis.
Generic manufacturers sign sublicences to produce long-acting HIV medicine
Sublicence agreements signed by the Medicines Patent Pool (MPP) and three generic manufacturers could enable millions to access a long-acting HIV medicine.
Innovative mass spectrometry method facilitates accurate C. auris identification
A novel high resolution mass spectrometer can accurately identify one of most common nosocomial fungal pathogens, researchers have found.
Biopharma could reap benefits from SVB UK acquisition
One of the largest banking collapses in US history could provide the biotech sector unseen opportunities, say GlobalData.
GSK to exclusively license novel oral antifungal
The only US Food and Drug Administration (FDA)-approved oral antifungal for vulvovaginal candidiasis will be exclusively licensed by GSK.
Novel delivery approach demonstrates efficacy of immunotherapy
A first-in-human study showed a novel approach for delivering intrathecal and intravenous immunotherapy improved survival of melanoma patients with leptomeningeal disease (LMD).
£277m investment to advance UK life sciences manufacturing
Four UK life sciences companies are set to benefit from a £277m investment in the first tranche of Life Sciences Innovative Manufacturing Fund (LSIMF) grants.
First immunotherapy recommended for advanced cervical cancer
Final draft guidance published by the National Institute for Health and Care Excellence (NICE) has recommended immunotherapy pembrolizumab drug for advanced cervical cancer.
